Washington, D.C. – U.S. Senator Catherine Cortez Masto (D-Nev.) released the following statement applauding yesterday’s passage of the Right Rebate Act in the Senate as part of the Medicaid Services Investment and Accountability Act of 2019. The Right Rebate Act, introduced by Senators Ron Wyden (D-Ore.) and Chuck Grassley (R-Iowa), strengthens congressional oversight of drug companies and closes a Medicaid loophole that has permitted pharmaceutical manufacturers to misclassify drugs and grossly overcharge Medicaid for life-saving medicines.
“One of the biggest concerns I hear from Nevadans is the rising costs of prescription medicines. Congressional oversight over pharmaceutical companies is crucial to stop manufacturers from intentionally misclassifying life-saving drugs in order to charge patients more for the medicines they need to stay healthy. I’m proud to support this legislation that helps strengthen protections for Medicaid patients and American taxpayers from being overcharged for prescription drugs. We must have more action in the Senate to hold pharmaceutical companies accountable and ensure affordable prescription drugs for Nevadans, and all Americans.”